Acute effects of Nitrosigine® and citrulline malate on vasodilation in young adults

Table 2 ANOVA results for all FMD variables

Variable	Pre-Supplement	Post-Supplement	p-value Supplement x Time Interaction	p-value Supplement Effect
Flow-Mediated Dilation (%)
Citrulline Malate	7.15 ± 2.44	9.60 ± 2.72	< .001	< .001^a
Nitrosigine	8.00 ± 3.14	10.48 ± 2.63		< .001^a
Placebo	8.01 ± 2.90	7.87 ± 2.83		.76^b
Allometric Scaled FMD %
Citrulline Malate	7.09 ± 1.80	8.85 ± 1.98	< .001	< .001^a
Nitrosigine	7.65 ± 2.16	9.47 ± 1.84		< .001^a
Placebo	7.69 ± 2.17	7.65 ± 2.07		.90^b
AUC Hyperemic Shear Rate to Maximum (∫ sec⁻¹)
Citrulline Malate	164,109 ± 175,726	269,706 ± 217,793	.30	.01^a
Nitrosigine	245,539 ± 190,582	288,877 ± 199,491		.29^b
Placebo	318,179 ± 205,705	311,804 ± 224,332		.92^b
Maximum Shear Rate (sec⁻¹)
Citrulline Malate	771.97 ± 310.45	786.70 ± 253.42	.86	.75^a
Nitrosigine	812.08 ± 376.58	790.26 ± 268.38		.76^a
Placebo	918.25 ± 490.64	914.91 ± 367.76		.99^a

Note. FMD flow-mediated dilation. Values are reported as mean + SD. Values with different letters represent statistically significant values

ISSN: 1550-2783